Recently, Efung Capital has successively received multiple industry honors from Entrepreneur (创业邦), China Fund News (中国基金报), 36Kr, and Haoyue (浩悦); CEO Mr. Zhu Pai was named to 36Kr's Top 20 Chinese Life Science Industry Investors. (Listed in order of announcement date.)
【Entrepreneur (创业邦)】 For the sixth consecutive year, the "Most Admired Venture Capital Institutions" selection was launched. It pioneered the "peer review" mechanism in the industry, handing important judging power to investors on the market frontline, observing institutions' professional capabilities and industry reputation from a peer perspective, and screening benchmark institutions with solid performance, professional capabilities, and brand reputation for the market.
Efung Capital was honored with:
Entrepreneur (创业邦)
2026 Most Admired Venture Capital Institution
Entrepreneur (创业邦)
2026 Most Admired Venture Capital Institution
【China Fund News (中国基金报)】 The Equity Venture Capital and Private Equity "Yinghua" Demonstration Case Series aims to establish industry benchmarks in venture capital and private equity investment, expand social awareness of equity venture capital, and promote standardized industry development.
Efung Capital was honored with:
China Fund News (中国基金报)
Healthcare Industry Investment Demonstration Institution
China Fund News (中国基金报)
Outstanding Equity Private Equity Demonstration Institution
【36Kr Venture Capital Research Institute (36氪创投研究院)】 has long tracked domestic primary market industrial investment trends and has published authoritative industrial investment directories for many consecutive years. This year's "Industrial Investment Industry" series directory selection is open to all primary market investment institutions and frontline investors, objectively documenting the true force of industrial and capital co-development.
Efung Capital was honored with:
36Kr
China Life Manufacturing Industry Investment Institution TOP20
Efung Capital CEO Zhu Pai was honored with:
36Kr
China Life Science Industry Investor TOP20
【Zhuoyue List (卓悦榜)】 As an important bellwether for evaluating corporate market value and institutional brand influence in the healthcare investment industry, since its first release in 2017, it has always adhered to the principles of fairness, impartiality, and objective neutrality, awarding institutions and healthcare enterprises that have performed outstandingly and made outstanding contributions each year.
Efung Capital was honored with:
Haoyue – Annual Healthcare
Best Return on Investment Institution
Haoyue – Innovative Devices and Life Sciences
Best Institution Award
Haoyue
Annual Best Innovative Pharmaceutical Institution Award
Investment in the healthcare industry has long return cycles and high uncertainty. True value creation often takes five, ten, or even longer years to manifest. Efung will continue to uphold a long-term investment philosophy, empowering innovation with capital, safeguarding value with professionalism, and continuously promoting the high-quality development of China's healthcare industry.
【Disclaimer】
The content of this article represents only the Company's views based on currently available public information and materials provided by portfolio companies. It does not constitute any investment advice, medical advice, or guarantee of specific corporate performance. Investment involves risks; caution is advised when entering the market. Readers should make independent judgments based on public information. Unauthorized reproduction or commercial use is prohibited.